HIMS Hims & Hers Health, Inc.
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. The company was formerly known as Hims, Inc. and changed its name to Hims & Hers Health, Inc. in January 2021. The company was founded in 2017 and is based in San Francisco, California.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Hims & Hers Health (NYSE: HIMS)
›
Hims & Hers Health (NYSE: HIMS) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 2,442 employees.
The shares were at 16.02 USD on 19 November 2026, down 56.7% over 52 weeks. Its 52-week range is 13.74 USD to 40.99 USD: the price is 60.9% below the high and 16.6% above the low.
Its market capitalisation is 3.76B USD.
Hims & Hers Health reports return on equity of 23.7%, an operating margin of -6.4% and revenue up 48.6% year over year.
Its debt exceeds its cash by 848.53M USD, a debt-to-equity ratio of 2.07. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 13 analysts cover the stock, with an average rating of Hold; their mean price target of 28.31 USD is 76.7% above the current price. The next earnings report is expected on 1 March 2027.